|
|
|
|
|
|
|
|
|
Bispecific antibodies (BsAbs) have become increasingly of interest for therapeutic applications. While natural antibodies are monospecific, bispecific antibodies recognize two different epitopes either on the same or on different antigens. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including various engineering of antibody fragments in symmetric or asymmetric manner.
|
|
Bispecific antibody mechanism of action: BsAbs bind two different types of antigen.
|
|
BsAb showed in the picture showed one arm binding tumor antigen and the other binding CD3 determinant on surface of a T cell. This cross-linking of tumor and effector cells increases their proximity while simultaneously triggering T cell activation. The result is a targeted and highly effective tumor cell killing.
Bispecific antibodies:
|
|
|
Superior Potency through Novel MOA
|
|
|
|
|
Low off-target binding reduces side effects
|
|
|
|
|
Develop only 1 molecule and save 1/2 of investment in comparison with combination therapy
|
|
|
|
|
|
|
|
Click the webinar below to register and lean the major benefits of bispecific antibodies and case study from rational design to preclinical development.
|
|
|
|
|
|
|
Follow GenScript Asia Pacific on LinkedIn
|
|
|
|
|
|
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Pharmaceutical Technology, an MJH Life Sciences™ brand. You are on the mailing list as %%emailaddress%%.
|
|
|
|
